Blood & Marrow Transplant (BMT) Clinic
The Bone Marrow Transplant, Cellular and Gene Therapy Program provides life-saving therapies for children with a variety of conditions, including blood cancers; noncancerous blood conditions, such as primary immune deficiency disorders, sickle cell disease, beta thalassemia and aplastic anemia; brain tumors and other solid tumors; and certain rare metabolic and genetic disorders.
These cutting-edge therapies often involve providers from many specialties. Drawing on expertise across multiple disciplines allows us to deliver optimal care before, during and after the course of treatment.
Why families choose us
Outstanding bone marrow transplant (BMT or stem cell transplant) outcomes
- Our BMT patients have among the highest survival rates in the nation, thanks to our commitment to thorough pretransplant evaluation and preparation and post-transplant follow-up care.
Pioneers in cellular therapies
- We were the first medical center in California certified to deliver CAR T-cell therapy to pediatric patients outside of a clinical trial.
Leaders in gene therapy
- UCSF was one of the first medical centers to offer newly-approved gene therapies for sickle cell disease and is at the forefront of research into potentially curative gene-correcting treatments.
Commitment to success
- All our patients receive personalized chemotherapy dosing and robust supportive care, measures that contribute to our high survival rates.
Support for families
Recognizing that optimal care isn't just about treating a disease, our program is designed to ease the medical journey for patients and families:
- We work to provide seamless care, both within and outside our local communities, serving patients and referring doctors well beyond the San Francisco Bay Area, thanks to our comprehensive telehealth system.
- Specialized multidisciplinary clinics ensure that patients with rare metabolic disorders or severe graft-versus-host disease get the comprehensive care and support they need.
- Dedicated patient navigators help families with managing referrals, insurance concerns and appointment planning.
Awards & recognition
-
Top 10 in the nation and best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
-
Designated an early phase clinical trials core site by the Children's Oncology Group
-
Accredited by the Foundation for Accreditation of Cellular Therapy
Our locations (2)
Our team
-
Julia Chu
MD, MPH
Pediatric Hematology Oncology -
Morton J. Cowan
MD
Pediatric Allergy and Immunology -
Christopher Dvorak
MD
Pediatric Hematology, Medical Oncology -
Christine Higham
MD
Pediatric Hematology Oncology -
James Huang
MD
Pediatric Hematology Oncology -
Sandhya Kharbanda
MD
Pediatric Hematology -
Gabriel Salinas Cisneros
MD
Pediatric Hematology Oncology -
Kristin A. Shimano
MD
Medical Oncology, Hematology -
Mark Walters
MD
Pediatric Hematology Oncology -
Lena Winestone
MD, MPH
Pediatric Hematology, Pediatrics -
Mara Bailey-Olson
CPNP
Pediatric Cellular Therapy -
Janelle Facchino
NP, MS
Pediatric Cellular Therapy -
Brianne Gebhardt
NP, BSN
Pediatrics -
Sara O'Kane
NP
Anemia and Bone Marrow Disorders
Plan your visit
Related clinics (7)
7
Hematology Clinic
Primary Immune Regulatory Disorder (PIRD) Clinic
Support services
Patient stories
Precision treatment helps kids with blood cancer
A cutting-edge therapy developed at UCSF minimizes the amount of chemotherapy kids like Astrid King need to beat blood cancer.
Clinical trials
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...
The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.
Recruiting
More about this studyAutologous Gene Therapy for Artemis-Deficient SCID
Patient survival status and (if applicable) cause of death will be recorded to assess overall survival.
Recruiting
More about this studyA Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
The cumulative incidence of Grade III-IV acute GVHD at Day 100 will be summarized by incidence curves. GVHD evaluations will be performed using standard criteria.37 Patients with graft rejection will be censored.
Recruiting
More about this studyA Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Trans...
Clinically significant CMV is defined as the first of (1) initiation of anti-CMV preemptive therapy for documented CMV DNAemia or (2) onset of CMV end-organ disease. Will estimate the cumulative incidence of clinically significant...
Recruiting
More about this studyTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoi...
The adverse event rate will be summarized using descriptive statistics, together with 95% confidence intervals where appropriate. No formal statistical hypothesis testing will be performed. Adverse events defined: failure of engra...
Recruiting
More about this studyChemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
to assess overall response rate following chemoimmunotherapy induction therapy
Recruiting
More about this studyEBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Patients will be monitored for adverse events related to the infusion of EBV CTLs
Recruiting
More about this studyStress Hydrocortisone In Pediatric Septic Shock
Appearance of new or progression of existing organ dysfunctions according to PELOD-2 definitions. PELOD-2 considers 5 organ dysfunctions (neurological, cardiovascular, renal, respiratory, and hematological) with 10 total variables...
Recruiting
More about this studyAzithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
Duration of hospitalization in days for enrolled subjects
Recruiting
More about this studyOur research initiatives
Smell the roses
Wander outside into our Butterfly Garden in Oakland and our healing gardens at Mission Bay.
